Enhancing Precision Health Data Discoverability and Usability:
The Collaborative Efforts of DNAnexus and Panomics
Wednesday, April 17 at 12:40 pm
Managing multimodal data securely, efficiently and ethically is paramount in the rapidly evolving biopharmaceutical landscape. This presentation delves into the collaborative efforts of DNAnexus and Panomics, showcasing their state-of-the-art solutions for managing, analyzing and collaborating on multimodal data nested under the safeguards of trusted research environments.
We will explore how together we empower researchers by streamlining data cataloging and ensuring adherence to FAIR (Findable, Accessible, Interoperable, and Reusable) principles and GxP compliance. Through case studies, we will demonstrate the transformative impact of these technologies on data management, emphasizing enhanced accessibility, interoperability, and innovation in biopharmaceutical R&D.
Speaker:
Nirav Amin
Director of Solution Science
DNAnexus
Speaker
Speaker
BIOINFORMATICS FOR PRECISION MEDICINE
Tuesday, April 16 at 11:10 pm
Thinking through the Models and Data Needed to Answer Your Pharmacogenomics Questions
Speaker:
Benjamin R. Busby, PhD
Director, Solution Science
DNAnexus, Inc
LARGE LANGUAGE MODELS: HYPE VS. REALITY IN PHARMA R&D
Tuesday, April 16 at 3:30 pm
PANEL DISCUSSION: Pharma Knowledge Graphs and Large Language Models: Antagonistic or Synergistic?
PANEL MODERATOR:
Tom Plasterer, PhD, Director, Bioinformatics, Data Science & AI, Biopharmaceutical R&D, AstraZeneca
While powerful, knowledge graphs require deep expertise to assemble and are challenging to maintain. Conversely, large language models can “learn” from a broad corpus but may hallucinate for under-trained queries. Are these two paradigms incompatible or can they be made synergistic? In 2023 an impromptu expert panel debated the relative benefits/drawbacks of both. A year onwards, substantial synergistic progress occurred. We will debate the landscape's transformation throughout the year.
PANELISTS:
Benjamin R. Busby, PhD, Director, Solution Science, DNAnexus, Inc.
Helena Deus, PhD, Lead for Semantic Data Products, Bristol Myers Squibb
Brian Martin, Head of AI, R&D Information Research; Research Fellow, AbbVie, Inc.
The UK Biobank Story:
Transforming Future Health
Tuesday, April 16th at 3:30pm
UK Biobank is a large-scale cohort study and biomedical database and is one of the world’s most important and widely-used health research resources, containing a wealth of data on genomics, lifestyle factors and health outcomes on half a million participants. Its unique combination of scale, depth, maturity, and accessibility is far ahead of any comparable biological resources (and will remain so for many years to come). As a result, more than 30,000 researchers (10,000 in the US) from around the world are using UK Biobank, with exponential growth in publications and patents now emerging from it.
20 years from its initiation, UK Biobank has surpassed all expectations for its extraordinary impact on increasing understanding of the determinants of disease, identifying factors that can predict future disease risk more accurately and identifying early disease biomarkers. During the next 5 years, UK Biobank would like to increase the depth of characterization of various types of risk factors for disease, and of the many different types of health outcome occurring in participants in order to substantially increase its value for discovery science.
Speaker:
Naomi Allen, DPhil, MSc, BSc,
Professor of Epidemiology, Nuffield Department, Population Health, University of Oxford;
Chief Scientist, UK Biobank, Cancer Research UK Epidemiology Unit, University of Oxford
Speaker
Session:
Innovative Practices Awards Winner: Global Impact Award Category
500k Whole-Genome Sequencing Data Release on UK Biobank Research Analysis Platform (Powered by DNAnexus)
Wednesday, April 17, at 10:58am
Speaker:
Asha Collins
SVP & General Manager, Biobanks
DNAnexus
